Reshaping the HIV treatment and prevention landscape
Internal R&D innovation complemented by BD
Strengthening the pipeline
-
Two-fold increase in deals (2018-21 vs. 2015-17) resulting in:
-
- 2 approved medicines, 1 Phase 3 asset and >10 Phase 1
or Phase 2 assets
Our deals are enabling:
-
Creation of synthetic lethality pipeline and research unit
- Acceleration of immuno-oncology portfolio
- Access to key platform technologies e.g. mRNA, ADCs,
ASOS, T cell therapies
CUREVAC
IONIS
the RNA people
NIR AnaptysBio
Enhancing technology capabilities
-Built state-of-the-art human genetics, functional genomics
and AI/ML capabilities
-
-
Over 40 early-stage programmes with 23andMe
Programs with UCSF, UC Berkeley, the Broad Institute
- >70% of research pipeline is genetically validated
SURFACE
ONCOLOGY.
iTeos
TM
23andMe
Lyell
BROAD
Therapeutics
INSTITUTE
Seagen SpringWorks IDEA VA MERCK
BIOSCIENCES
Adaptimmune
TRANSFORMING T CELL THERAPY
immatics
Continued focus on BD to strengthen pipeline
NVIDIA®
ADRESTIA
THERAPEUTICS
Laboratory
for Genomics
Research
iTeos Therapeutics collaboration subject to regulatory clearance
Logo's representative of sample of key BD deals
gsk
cerebras
ALTIVS
54View entire presentation